194 related articles for article (PubMed ID: 17333295)
1. Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study.
Ripamonti C; Fagnoni E; Campa T; Giardina V; Brunelli C; Pigni A; De Conno F
Support Care Cancer; 2007 Oct; 15(10):1177-84. PubMed ID: 17333295
[TBL] [Abstract][Full Text] [Related]
2. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study.
Ripamonti C; Fagnoni E; Campa T; Seregni E; Maccauro M; Bombardieri E
Support Care Cancer; 2007 Mar; 15(3):339-42. PubMed ID: 16967302
[TBL] [Abstract][Full Text] [Related]
3. EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid.
Yeh DC; Chen DR; Chao TY; Chen SC; Wang HC; Rau KM; Feng YH; Chang YC; Lee KD; Ou-Yang F; Kuo WH; Chang KJ; Lin YC; Tseng LM; Hou MF
In Vivo; 2014; 28(5):1001-4. PubMed ID: 25189922
[TBL] [Abstract][Full Text] [Related]
4. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
Leto G; Badalamenti G; Arcara C; Crescimanno M; Flandina C; Tumminello FM; Incorvaia L; Gebbia N; Fulfaro F
Anticancer Res; 2006; 26(1A):23-6. PubMed ID: 16475674
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan.
Chiang PH; Wang HC; Lai YL; Chen SC; Yen-Hwa W; Kok CK; Ou YC; Huang JS; Huang TC; Chao TY
J Cancer Res Ther; 2013; 9(4):653-9. PubMed ID: 24518712
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
7. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
Hong SJ; Cho KS; Cho HY; Ahn H; Kim CS; Chung BH
Yonsei Med J; 2007 Dec; 48(6):1001-8. PubMed ID: 18159593
[TBL] [Abstract][Full Text] [Related]
8. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL
JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702
[TBL] [Abstract][Full Text] [Related]
9. Percutaneous vertebroplasty combined with zoledronic acid for the treatment of painful osteolytic spinal metastases in patients with breast cancer.
Zhang J; Wang Y; Han K; Tang L; Hu H; Wu C; Shen Z; Sun Y; Yao Y
J Vasc Interv Radiol; 2013 Dec; 24(12):1861-7. PubMed ID: 24144536
[TBL] [Abstract][Full Text] [Related]
10. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
Cleeland CS; Body JJ; Stopeck A; von Moos R; Fallowfield L; Mathias SD; Patrick DL; Clemons M; Tonkin K; Masuda N; Lipton A; de Boer R; Salvagni S; Oliveira CT; Qian Y; Jiang Q; Dansey R; Braun A; Chung K
Cancer; 2013 Feb; 119(4):832-8. PubMed ID: 22951813
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M
Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
14. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
[TBL] [Abstract][Full Text] [Related]
15. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
Polascik TJ; Given RW; Metzger C; Julian SR; Vestal JC; Karlin GS; Barkley CS; Bilhartz DL; McWhorter LT; Lacerna LV
Urology; 2005 Nov; 66(5):1054-9. PubMed ID: 16286123
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
Wardley A; Davidson N; Barrett-Lee P; Hong A; Mansi J; Dodwell D; Murphy R; Mason T; Cameron D
Br J Cancer; 2005 May; 92(10):1869-76. PubMed ID: 15870721
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
Storto G; Klain M; Paone G; Liuzzi R; Molino L; Marinelli A; Soricelli A; Pace L; Salvatore M
Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study.
Atahan L; Yildiz F; Cengiz M; Kaplan B; Ozkan M; Yazici G; Gündoğ M; Haydaroğlu A; Korcum AF; Sengöz M; Dinçer M; Akmansu M; Engin K; Hayran M
Support Care Cancer; 2010 Jun; 18(6):691-8. PubMed ID: 19484483
[TBL] [Abstract][Full Text] [Related]
20. [Use of zoledronic acid in patients with prostate cancer bone metastases: control of pain and musculoskeletal complications].
Paparella S; Finkelberg E; Varisco D; Tondelli E; Rocco F
Urologia; 2011; 78(4):300-4. PubMed ID: 22139807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
